ZA200805908B - Novel Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors - Google Patents

Novel Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Info

Publication number
ZA200805908B
ZA200805908B ZA200805908A ZA200805908A ZA200805908B ZA 200805908 B ZA200805908 B ZA 200805908B ZA 200805908 A ZA200805908 A ZA 200805908A ZA 200805908 A ZA200805908 A ZA 200805908A ZA 200805908 B ZA200805908 B ZA 200805908B
Authority
ZA
South Africa
Prior art keywords
derivatives
uptake inhibitors
monoamine neurotransmitter
novel chromen
chromen
Prior art date
Application number
ZA200805908A
Other languages
English (en)
Inventor
Peters Dan
Redrobe John Paul
Nielsen Elsebet Oestergaard
Original Assignee
Neurosearch As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch As filed Critical Neurosearch As
Publication of ZA200805908B publication Critical patent/ZA200805908B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
ZA200805908A 2006-02-17 2007-02-13 Novel Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors ZA200805908B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA200600233 2006-02-17

Publications (1)

Publication Number Publication Date
ZA200805908B true ZA200805908B (en) 2009-10-28

Family

ID=39272807

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200805908A ZA200805908B (en) 2006-02-17 2007-02-13 Novel Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Country Status (15)

Country Link
US (1) US8153797B2 (no)
EP (2) EP1989202B1 (no)
JP (1) JP2009526816A (no)
KR (1) KR20080096833A (no)
CN (1) CN101405287B (no)
AR (1) AR059546A1 (no)
AU (1) AU2007216535A1 (no)
BR (1) BRPI0707853A2 (no)
CA (1) CA2641916A1 (no)
IL (1) IL192485A0 (no)
NO (1) NO20083955L (no)
RU (1) RU2008129865A (no)
TW (1) TW200800980A (no)
WO (1) WO2007093604A1 (no)
ZA (1) ZA200805908B (no)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007002384A (es) * 2004-09-30 2007-05-11 Neurosearch As Nuevos derivados de cromen-2-ona y su uso como inhibidores de la reabsorcion del neurotransmisor de monoamina.
AU2007336291A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008074797A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
AU2010247514A1 (en) * 2009-05-15 2011-11-17 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011092061A1 (en) 2010-01-29 2011-08-04 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2011117289A1 (en) 2010-03-25 2011-09-29 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neuro-transmitter re-uptake inhibitors
WO2012000881A1 (en) 2010-07-02 2012-01-05 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8923209D0 (en) * 1989-10-14 1989-11-29 Wyeth John & Brother Ltd Heterocyclic compounds
SK282944B6 (sk) 1995-11-02 2003-01-09 Neurosearch A/S Tavené tropánové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
KR100446571B1 (ko) 1996-02-22 2004-11-03 뉴로서치 에이/에스 트로판-유도체,이의제조방법및이를포함하는약제학적조성물
US5916914A (en) * 1997-08-08 1999-06-29 Warner-Lambert Company Compounds and method of treating psychosis and schizophrenia
US20040106643A1 (en) * 2001-05-23 2004-06-03 Gouliaev Alex Haarh Tropane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US6921821B2 (en) 2002-06-12 2005-07-26 Abbott Laboratories Antagonists of melanin concentrating hormone receptor
US7538233B2 (en) 2003-09-05 2009-05-26 Aventis Pharmaceuticals Inc. Coumarins as iNOS inhibitors
CA2582297A1 (en) 2004-09-30 2006-04-06 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
US7781456B2 (en) 2004-12-17 2010-08-24 Neurosearch A/S Enantiomers of 3-heteroaryl-8H-8-azabicyclo(3.2.1)oct-2-ene and their use as monoamine neurotransmitter re-uptake inhibitors
AU2007336291A1 (en) 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
WO2008074797A1 (en) 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
NO20083955L (no) 2008-09-16
US8153797B2 (en) 2012-04-10
AU2007216535A1 (en) 2007-08-23
IL192485A0 (en) 2009-02-11
RU2008129865A (ru) 2010-03-27
EP1989202A1 (en) 2008-11-12
AR059546A1 (es) 2008-04-09
EP2311835A1 (en) 2011-04-20
JP2009526816A (ja) 2009-07-23
WO2007093604A1 (en) 2007-08-23
BRPI0707853A2 (pt) 2011-05-10
US20100227883A1 (en) 2010-09-09
CA2641916A1 (en) 2007-08-23
TW200800980A (en) 2008-01-01
CN101405287A (zh) 2009-04-08
EP1989202B1 (en) 2012-07-25
KR20080096833A (ko) 2008-11-03
CN101405287B (zh) 2011-05-18

Similar Documents

Publication Publication Date Title
GB0700919D0 (en) Degradable compositions, apparatus comprising same, and methods of use
IL192613A0 (en) Cycloalkylamines as monoamine reuptake inhibitors
PL2040728T3 (pl) FKBP-L i jego zastosowanie jako inhibitora angiogenezy
IL195619A0 (en) Compositions and methods for joininig non-conjoined iumens
ZA200807447B (en) Thieno-Pyridine derivatives as MEK inhibitors
EP1978961A4 (en) MONOAMINE RECORDING INHIBITORS ON TETRALON BASIS
HK1137756A1 (en) Substituted dihydropyrazolones and use thereof as hif-prolyl-4 -hydroxylase inhibitors hif--4-
HK1138616A1 (en) Novel laccases, compositions and methods of use
GB0601143D0 (en) Uses, methods and compositions
PL2078001T3 (pl) Pochodne diazepano-acetamidowe jako selektywne inhibitory 11-hsd1
EP2239261A4 (en) PYRROLOPYRIMIDINE DERIVATIVE FOR USE AS A PI3K INHIBITOR AND USE THEREOF
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
IL197528A0 (en) Synthesis, methods of using, and compositions of cycloalkylmethylamines
IL196000A0 (en) 2-arylindole derivatives as npges-i inhibitors
IL192485A0 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
GB0617171D0 (en) Novel compositions and methods
IL209406A0 (en) Novel tetramethyl substituted piperidine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
EP2088865A4 (en) METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS
IL195014A0 (en) Benzazepine derivatives as monoamine reuptake inhibitors
HK1112918A1 (en) Benzofuranyl derivatives as 5-ht6-receptor inhibitors
ZA200806434B (en) Calcium-enrichment compositions and methods for production thereof
IL198762A0 (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
ZA200903278B (en) Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL180777A0 (en) Novel chromen-2- one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
IL178734A0 (en) Novel alkyl substituted piperazine derivatives and their use as monoamine neurotransmitter re-uptake inhibitors